Quest Diagnostics Incorporated (DGX) |
| 179.96 4.02 (2.28%) 01-13 16:00 |
| Open: | 176.86 |
| High: | 180.4 |
| Low: | 175.47 |
| Volume: | 811,583 |
| Market Cap: | 20,110(M) |
| PE Ratio: | 21.12 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 215.89 |
| Resistance 1: | 184.84 |
| Pivot price: | 176.12 |
| Support 1: | 176.40 |
| Support 2: | 171.18 |
| 52w High: | 197.55 |
| 52w Low: | 148.7 |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| EPS | 8.520 |
| Book Value | 65.390 |
| PEG Ratio | 0.00 |
| Gross Profit | 32.632 |
| Profit Margin (%) | 8.93 |
| Operating Margin (%) | 14.91 |
| Return on Assets (ttm) | 6.1 |
| Return on Equity (ttm) | 14.4 |
Tue, 13 Jan 2026
Baird Adjusts Quest Diagnostics Price Target to $203 From $198, Maintains Neutral Rating - marketscreener.com
Sat, 10 Jan 2026
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why - Eastern Progress
Sat, 10 Jan 2026
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Eastern Progress
Fri, 09 Jan 2026
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 - BioSpace
Fri, 09 Jan 2026
Quest Diagnostics (NYSE:DGX) Could Be A Buy For Its Upcoming Dividend - Sahm
Thu, 08 Jan 2026
Quest Diagnostics (NYSE:DGX) Could Be A Buy For Its Upcoming Dividend - simplywall.st
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |